Pfizer reports positive paediatric epilepsy data for Lyrica

Pfizer has announced new clinical trial data that highlights the strong performance of its drug Lyrica in the treatment of paediatric epilepsy.

The phase III study aimed to assess the performance of capsule and oral solution-based formulations of Lyrica as an adjunctive therapy for paediatric epilepsy patients aged four to 16 years with partial-onset seizures.

Treatment with a 10 mg dose of Lyrica was shown to result in a statistically significant reduction in seizure frequency versus placebo, thereby meeting the primary efficacy endpoint of the trial, while a 2.5 mg dose resulted in a smaller seizure frequency reduction.

Currently, Lyrica is not approved as adjunctive therapy for paediatric epilepsy patients with partial onset seizures, but findings such as these could make this possible in future.

Dr Rory O'Connor, chief medical officer for internal medicine at Pfizer, said: "Epilepsy remains a common and debilitating condition worldwide, and these results make a substantial contribution to the body of evidence for Lyrica in the paediatric population."

The Lyrica paediatric epilepsy programme is composed of a total of six studies, three of which have been completed, with the other three still actively enrolling patients.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.